IPO • Life Science

Teva Pharmaceutical Industries Exits Immuneering

On July 29, 2021, invested in life science company Immuneering from Teva Pharmaceutical Industries

Investment Context
  • This is transaction in the Life Science sector.
  • This is transaction in the United States.
  • This is transaction in Massachusetts.

Explore All 295 IPO Life Science Deals - Search the Database Free


Investment Summary

Date July 29, 2021
Target Immuneering
Sector Life Science
Sellers(s) Teva Pharmaceutical Industries
Deal Type IPO

Target Company

Immuneering

Cambridge, Massachusetts, United States
Immuneering is a trusted advisor to pharmaceutical companies, pioneering new analyses to identify biological insights that improve patients’ lives. Immuneering’s team of experts provides advanced data analysis services using state-of-the-art technologies including proprietary algorithms. The company is a rapidly growing company with seven years of experience analyzing data sets ranging from gene expression (microarray) data, to single-nucleotide polymorphism (SNP) data, to protein concentration data, to clinical metadata, to next-generation sequencing (NGS) data including RNA seq, exome sequencing, and whole-genome sequencing. Using these data sets, Immuneering captures difficult-to-find signals, generates biological hypotheses, and designs follow-up studies, contributing to the development of medicines for patients with a wide range of serious diseases. Immuneering was formed in 2008 and is based in Cambridge, Massachusetts.
Explore More Deals

Browse All 215,158 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Seller Profile 1

SELLER

Teva Pharmaceutical Industries

Tel Aviv, Israel

Category Company
Founded 1901
Sector Life Science
Employees37,000
Revenue 16.5B USD (2024)
DESCRIPTION

Teva Pharmaceutical Industries is a provider of pharmaceutical products, committed to increasing access to high-quality healthcare by developing, producing, and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Teva Pharmaceutical Industries was founded in 1901 and is based in Tel Aviv, Israel.


Deal Context for Seller #
Overall 9 of 9
Sector: Life Science 8 of 8
Type: IPO 1 of 1
State: Massachusetts 1 of 1
Country: United States 3 of 3
Year: 2021 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-04-01 Zdravlje

Leskovac, Serbia

Zdravlje is a manufacturer and supplier of high-quality pharmaceutical products. The Company currently manufactures a large portfolio of oral solid and liquid products to treat a range of serious and chronic diseases including cardiovascular, central nervous system, and respiratory disorders, amongst others. It supplies high-quality pharmaceuticals to more than 35 international markets including those in Western & Eastern Europe, U.K., Asia-Pacific, Sub-Saharan Africa, and Latin America. Zdravlje was formed in 1953 and is based in Leskovac, Serbia.

Sell -